Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: BEAM

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Analyst Ratings

Analyst Ratings for Beam Therapeutics

By Benzinga Insights
Today, 8:00 AM
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

BEAM

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Cantor Fitzgerald Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $62

By Benzinga Newsdesk
Today, 6:26 AM
Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Overweight rating and announces Price Target of $62.

BEAM

Read More
1 minute read
  • News

Beam Therapeutics Reports Progress Across Base Editing Portfolio And Outlines Key Anticipated Milestones

By Benzinga Newsdesk
January 9, 7:42 AM
BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023   First Patient Dosing in BEAM-201 Trial in Patients with

BEAM

Read More
2 minute read
  • Biotech
  • Broad U.S. Equity ETFs
  • ETFs
  • General
  • Markets
  • News
  • Small Cap

Cathie Wood Gets Elon Musk’s Attention Over Gene-Editing Therapy Potential: ‘Investors Chased The Dream Then. Now, They’re Running Away’

By Bhavik Nair
January 5, 12:48 AM
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.

ARKG

Read More
1 minute read
  • Analyst Ratings

4 Analysts Have This to Say About Beam Therapeutics

By Benzinga Insights
December 20, 3:02 PM
Analysts have provided the following ratings for Beam Therapeutics (NASDAQ:BEAM) within the last quarter: Bullish Somewhat Bullish Indifferent…

BEAM

Read More
1 minute read
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • News
  • Price Target
  • Small Cap
  • Upgrades

Analyst Beefs Up Beam Therapeutics Price Target, Says ‘Reward Is Now Skewed To Upside’

By Vandana Singh
December 20, 2:51 PM
BMO Capital Markets has upgraded Beam Therapeutics Inc (NASDAQ:BEAM) from Market Perform to Outperform and raised the price target from $61 to…

BEAM

Read More
2 minute read
  • Analyst Ratings
  • Markets
  • News
  • Pre-Market Outlook
  • Price Target
  • Small Cap
  • Trading Ideas

Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday

By Lisa Levin
December 20, 9:05 AM
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close at $114.92 on Friday.

AAPL

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Upgrades

BMO Capital Upgrades Beam Therapeutics to Outperform, Raises Price Target to $66

By Benzinga Newsdesk
December 20, 8:20 AM
BMO Capital analyst Kostas Biliouris upgrades Beam Therapeutics (NASDAQ:BEAM) from Market Perform to Outperform and raises the price target from $61 to $66.

BEAM

Read More
24 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For December 13, 2022

By Benzinga Insights
December 13, 11:01 AM
Upgrades For Equinix Inc (NASDAQ:EQIX), Cowen & Co. upgraded the previous rating of Market Perform to Outperform. In…

AFRM

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Citigroup Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $62

By Benzinga Newsdesk
December 13, 9:26 AM
Citigroup analyst Samantha Semenkow initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $62.

BEAM

Posts navigation

1 2 … 10 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service